Clinical Trials Directory

Trials / Completed

CompletedNCT04499209

Pharmacokinetics Study of XG005 Capsule

A Phase 1, Single-Center, Randomized, Placebo-Controlled, Ascending Single-Dose Study of the Pharmacokinetics, Safety, and Tolerability of Oral XG005 in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Xgene Pharmaceutical Group · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This was a Phase 1, single-center, randomized, placebo-controlled, 2-period, ascending single-dose study assessing the PK, safety, and tolerability of single ascending doses of XG005 (Period 1) and the naproxen and pregabalin combination (Period 2), in 5 dose groups each with 10 subjects.

Detailed description

Period 1 was double-blind and randomized 8 subjects (1:1 allocation ratio by gender) to XG005 and 2 subjects (1:1 allocation ratio by gender) to placebo. Subjects were enrolled sequentially into a total of 5 ascending dose levels pending safety review, and PK review where possible, of Period 1 of the prior dose level. Sentinel dose participants (1 for XG005 and 1 for placebo) were included as the first dose administered at each dose level in Period 1. In Period 2, all subjects in the last three XG005 dose groups received approximate molar equivalents of naproxen and pregabalin corresponding to XG005 doses after a 7-day washout period. Period 2 was open-label with 10 subjects per group. PK blood samples in each treatment period were collected at 0 (pre-dosing), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hrs after drug administration.

Conditions

Interventions

TypeNameDescription
DRUGXG005XG005 Capsule
DRUGCombination of Naproxen and PregabalinNaproxen and Pregabalin are commercially available products with trade names of Aleve and Lyrica
DRUGPlacebosPlacebo Capsule

Timeline

Start date
2017-10-16
Primary completion
2018-01-18
Completion
2018-03-19
First posted
2020-08-05
Last updated
2020-08-18

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT04499209. Inclusion in this directory is not an endorsement.